{"entity":{"type":"insider","cik":"0001961273","url":"/insider/0001961273","json_url":"/insider/0001961273.json","name":"Lamy Patrick","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":16,"n_filings":12,"first":"2024-06-13","last":"2025-07-03","span_basis":"filed_date"},"name_variants":[{"name":"Lamy Patrick","source":"filing","n_filings":12,"first_seen":"2024-06-13","last_seen":"2025-07-03"}],"transactions":[{"id":4313738,"accession":"0000950170-25-094011","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-094011","line_url":"/filing/0000950170-25-094011#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001961273","owner_name":"Lamy Patrick","owner_display_name":"Lamy Patrick","owner_url":"/insider/0001961273","role":"Officer (Senior VP, Commercial Strategy)","role_mark":"O","role_mark_label":"Officer (Senior VP, Commercial Strategy)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Commercial Strategy","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":52.88,"price_display":"52.88","price_state":"stated","total_value":105760.0,"total_display":"105,760.00","total_whole":"105,760","shares_owned_after":29891.0,"shares_owned_after_display":"29,891","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-01","filed_date":"2025-07-03","scope":"insider"},{"id":4792659,"accession":"0000950170-25-088639","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-088639","line_url":"/filing/0000950170-25-088639#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001961273","owner_name":"Lamy Patrick","owner_display_name":"Lamy Patrick","owner_url":"/insider/0001961273","role":"Officer (Senior VP, Commercial Strategy)","role_mark":"O","role_mark_label":"Officer (Senior VP, Commercial Strategy)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Commercial Strategy","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":875.0,"shares_display":"875","price_per_share":54.59,"price_display":"54.59","price_state":"stated","total_value":47766.25,"total_display":"47,766.25","total_whole":"47,766","shares_owned_after":31698.0,"shares_owned_after_display":"31,698","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-20","filed_date":"2025-06-20","scope":"insider"},{"id":5075491,"accession":"0000950170-25-088206","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-088206","line_url":"/filing/0000950170-25-088206","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001961273","owner_name":"Lamy Patrick","owner_display_name":"Lamy Patrick","owner_url":"/insider/0001961273","role":"Officer (Senior VP, Commercial Strategy)","role_mark":"O","role_mark_label":"Officer (Senior VP, Commercial Strategy)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Commercial Strategy","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":54.13575,"price_display":"54.14","price_state":"stated","total_value":108271.5,"total_display":"108,271.50","total_whole":"108,272","shares_owned_after":33073.0,"shares_owned_after_display":"33,073","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-16","filed_date":"2025-06-20","scope":"insider","n_lines":2},{"id":4911915,"accession":"0000950170-25-085670","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-085670","line_url":"/filing/0000950170-25-085670#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001961273","owner_name":"Lamy Patrick","owner_display_name":"Lamy Patrick","owner_url":"/insider/0001961273","role":"Officer (Senior VP, Commercial Strategy)","role_mark":"O","role_mark_label":"Officer (Senior VP, Commercial Strategy)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Commercial Strategy","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":919.0,"shares_display":"919","price_per_share":53.999,"price_display":"54.00","price_state":"stated","total_value":49625.081,"total_display":"49,625.08","total_whole":"49,625","shares_owned_after":32573.0,"shares_owned_after_display":"32,573","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-10","filed_date":"2025-06-12","scope":"insider"},{"id":4661779,"accession":"0000950170-25-081774","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-25-081774","line_url":"/filing/0000950170-25-081774","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001961273","owner_name":"Lamy Patrick","owner_display_name":"Lamy Patrick","owner_url":"/insider/0001961273","role":"Officer (Senior VP, Commercial Strategy)","role_mark":"O","role_mark_label":"Officer (Senior VP, Commercial Strategy)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Commercial Strategy","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":50.314375,"price_display":"50.31","price_state":"stated","total_value":201257.5,"total_display":"201,257.50","total_whole":"201,258","shares_owned_after":33592.0,"shares_owned_after_display":"33,592","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-02","filed_date":"2025-06-04","scope":"insider","n_lines":3},{"id":4617998,"accession":"0000950170-25-077131","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-077131","line_url":"/filing/0000950170-25-077131#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001961273","owner_name":"Lamy Patrick","owner_display_name":"Lamy Patrick","owner_url":"/insider/0001961273","role":"Officer (Senior VP, Commercial Strategy)","role_mark":"O","role_mark_label":"Officer (Senior VP, Commercial Strategy)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Commercial Strategy","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":50.0,"price_display":"50.00","price_state":"stated","total_value":200000.0,"total_display":"200,000.00","total_whole":"200,000","shares_owned_after":33492.0,"shares_owned_after_display":"33,492","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-22","filed_date":"2025-05-23","scope":"insider"},{"id":5074816,"accession":"0000950170-25-068392","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-068392","line_url":"/filing/0000950170-25-068392","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001961273","owner_name":"Lamy Patrick","owner_display_name":"Lamy Patrick","owner_url":"/insider/0001961273","role":"Officer (Senior VP, Commercial Strategy)","role_mark":"O","role_mark_label":"Officer (Senior VP, Commercial Strategy)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Commercial Strategy","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8000.0,"shares_display":"8,000","price_per_share":42.493744,"price_display":"42.49","price_state":"stated","total_value":339949.952,"total_display":"339,949.95","total_whole":"339,950","shares_owned_after":36791.0,"shares_owned_after_display":"36,791","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-07","filed_date":"2025-05-09","scope":"insider","n_lines":2},{"id":4340585,"accession":"0000950170-25-033997","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-033997","line_url":"/filing/0000950170-25-033997#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001961273","owner_name":"Lamy Patrick","owner_display_name":"Lamy Patrick","owner_url":"/insider/0001961273","role":"Officer (Senior VP, Commercial Strategy)","role_mark":"O","role_mark_label":"Officer (Senior VP, Commercial Strategy)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Commercial Strategy","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":48.09,"price_display":"48.09","price_state":"stated","total_value":48090.0,"total_display":"48,090.00","total_whole":"48,090","shares_owned_after":33492.0,"shares_owned_after_display":"33,492","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-03","filed_date":"2025-03-05","scope":"insider"},{"id":4098959,"accession":"0000950170-25-010706","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-010706","line_url":"/filing/0000950170-25-010706#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001961273","owner_name":"Lamy Patrick","owner_display_name":"Lamy Patrick","owner_url":"/insider/0001961273","role":"Officer (Senior VP, Commercial Strategy)","role_mark":"O","role_mark_label":"Officer (Senior VP, Commercial Strategy)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Commercial Strategy","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":57.03,"price_display":"57.03","price_state":"stated","total_value":285150.0,"total_display":"285,150.00","total_whole":"285,150","shares_owned_after":33492.0,"shares_owned_after_display":"33,492","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-27","filed_date":"2025-01-29","scope":"insider"},{"id":2181970,"accession":"0000950170-24-138149","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-138149","line_url":"/filing/0000950170-24-138149#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001961273","owner_name":"Lamy Patrick","owner_display_name":"Lamy Patrick","owner_url":"/insider/0001961273","role":"Officer (Senior VP, Commercial Strategy)","role_mark":"O","role_mark_label":"Officer (Senior VP, Commercial Strategy)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Commercial Strategy","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":29.13,"price_display":"29.13","price_state":"stated","total_value":29130.0,"total_display":"29,130.00","total_whole":"29,130","shares_owned_after":34258.0,"shares_owned_after_display":"34,258","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-16","filed_date":"2024-12-18","scope":"insider"},{"id":2125874,"accession":"0000950170-24-136020","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-136020","line_url":"/filing/0000950170-24-136020#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001961273","owner_name":"Lamy Patrick","owner_display_name":"Lamy Patrick","owner_url":"/insider/0001961273","role":"Officer (Senior VP, Commercial Strategy)","role_mark":"O","role_mark_label":"Officer (Senior VP, Commercial Strategy)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Commercial Strategy","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":925.0,"shares_display":"925","price_per_share":30.79,"price_display":"30.79","price_state":"stated","total_value":28480.75,"total_display":"28,480.75","total_whole":"28,481","shares_owned_after":17858.0,"shares_owned_after_display":"17,858","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-10","filed_date":"2024-12-12","scope":"insider"},{"id":2851002,"accession":"0000950170-24-073183","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-073183","line_url":"/filing/0000950170-24-073183#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001961273","owner_name":"Lamy Patrick","owner_display_name":"Lamy Patrick","owner_url":"/insider/0001961273","role":"Officer (Senior VP, Commercial Strategy)","role_mark":"O","role_mark_label":"Officer (Senior VP, Commercial Strategy)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP, Commercial Strategy","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":569.0,"shares_display":"569","price_per_share":22.641,"price_display":"22.64","price_state":"stated","total_value":12882.729,"total_display":"12,882.73","total_whole":"12,883","shares_owned_after":18562.0,"shares_owned_after_display":"18,562","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-11","filed_date":"2024-06-13","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":16,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":16,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":16},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001744659","name":"Akero Therapeutics, Inc.","url":"/issuer/0001744659","role":"Officer (Senior VP, Commercial Strategy)","n_filings":12,"first_seen":"2024-06-13","last_seen":"2025-07-03"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001961273","retrieved_at":"2026-08-25T05:27:02+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}